UnitedHealth Group (UNH) Q1 FY26 earnings call: guidance and Q&A

Clarify if MA cost trend is running closer to the 7-8% historical range or the 10% pricing assumption, and identify areas of acceleration or moderation.

Tim Noel stated that overall trend is progressing in line with expectations, with modest favorability in government programs (including MA). Utilization patterns remain at elevated 2025 levels, with no inflection point, and the company is comfortable with its 10% pricing assumption for 2026.

“We're seeing some modest favorability in the government programs which would then include Medicare Advantage, commercial very consistent with from those expectations. It's really early right now.”

asked by Albert Rice · answered by Timothy Noel

Quantify the impact of acuity on medical trend, detail actions to address it, and confirm if this dynamic is specific to MA or across all products.

Tim Noel confirmed that acuity is a factor across all products. The company is using better tools to identify outlier patterns, engaging early with clinical programs and pain integrity programs, and taking network actions to address affordability, with good progress being made.

“What we've done is a couple of things. We talked in the Medicare Advantage space. of our product positioning, leading more towards HMO-based products as a means to be able to better manage outlier activity.”

asked by Kevin Fischbeck · answered by Timothy Noel

Identify the drivers of OptumHealth's outperformance in Q1 (contract/benefit vs. utilization) and explain why its earnings are now first-half weighted.

Krista Nelson attributed OptumHealth's outperformance to favorable medical trends from prior periods (due to specific clinical and medical management actions) and improved operating performance, including a 12% increase in patient-facing hours. The first-half weighting is due to OptenFinancial moving to OptumInsight, making OptumHealth's seasonality resemble risk businesses.

“First, we're seeing medical from prior periods restated favorably relative to our expectations. But this is actually largely concentrated in markets where we've really focused on clinical and medical management efforts.”

asked by Andrew Mok · answered by Krista Nelson

Confirm if OptumHealth's $1.3 billion adjusted earnings are comparable to the $1.575 billion guidance, clarify the split of PYD vs. run rate benefit, and assess OptumInsight/Rx performance against internal expectations.

Wayne DeVeydt confirmed the $1.3 billion is comparable. Krista Nelson noted PYD was favorable due to specific Q4 actions, and operating costs also improved. Wayne added that all four segments exceeded internal plans, highlighting that Q1 incentive compensation ($900 million vs. $35 million YoY) significantly burdened results, making external modeling challenging.

“I would say that all 4 segments did actually exceed our internal plan expectations.”

asked by Justin Lake · answered by Wayne DeVeydt

Inquire about confidence in MA margin recovery for 2027 given the final rate notice, and the company's participation in the GLP-1 balance program.

Bobby Hunter expressed appreciation for CMS changes but noted 2027 medical trend is still above funding levels. The aspiration for 2027 MA margin is the upper half of the 2-4% long-term range. UNH is in active dialogue with CMS/CMMI on the GLP-1 balance program, seeking a 'path to yes' despite challenges with the current structure.

“For 2027, our aspiration is to be in the upper half of the 2% to 4% long-term range and doing that while continuing to deliver the quality the value and delivering on the full expectations that I know that our members have of us.”

asked by Stephen Baxter · answered by Bobby Hunter

Understand why OptumInsight and OptumRx earnings are back-half weighted, and the impact of PBM legislation, including potential redomiciling of the GPO.

Wayne DeVeydt explained OptumInsight's weighting by decommissioning old products and reinvesting in AI, with benefits expected in H2. OptumRx is onboarding 800+ new clients, with full impact next year. Jon Mahrt stated PBM legislation impacts are included in guidance, the GPO is already US-domiciled, and UNH is leading on transparency and independent pharmacy stability.

“The one thing I would say on the slope is for OptumInsight, I would view this as what we're doing is a couple of things. One is slowly decommissioning old products that were not AI-based and reinvesting in those products through the investments.”

asked by Lisa Gill · answered by Wayne DeVeydt

Seek targets for AI-driven cost savings (e.g., SG&A) and whether AI investments could structurally shift OptumInsight's growth rate.

Sandeep Dadlani detailed the $1.5 billion AI investment, expecting a 2:1 return on internal programs, many within 12-18 months. He highlighted OptumInsight's AI-first products (Digital prior auth, Optum Real, AI consulting) are gaining significant external traction, suggesting a positive impact on growth.

“And we expect to return conservatively 2:1 on these programs over the next few years, many of them paying back within the next 12 to 18 months.”

asked by Ann Hynes · answered by Sandeep Dadlani

Inquire about the expected acceleration of AI savings in 2027/2028 and their impact on long-term target margins, and clarify what share repurchase amount was embedded in guidance.

Stephen Hemsley stated it's too early to give specific guidance on compounding AI effects but expects long-term positive impact and productivity. Wayne DeVeydt clarified that the original guidance included $2.5 billion in buybacks, back-half loaded, and the $2 billion by Q2 represents an acceleration, not a change to the total guidance.

“Relative to capital deployment, our original guidance was approximately $2.5 billion back half loaded. So think of later Q3, Q4. At this stage with the intrinsic value discount we see -- we thought it was important for shareholders that we would get at that sooner and the confidence we have in our results.”

asked by Erin Wright · answered by Wayne DeVeydt